reports
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufact...
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an award valued up to $339M from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Departm...
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCH...
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations - Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeu...
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan fo...
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza - Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval - Phase 3 study population expanded to include adults over 65 years of age in addition to subjects with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cidar...
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE ...
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting - Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation - Preclinical data demonstrating potential efficacy of CD388 to prevent H5N1 infection featured in oral presentation SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop...
Fuel Tech to Present at H.C. Wainwright 27th Annual Global Investment ...
Fuel Tech to Present at H.C. Wainwright 27th Annual Global Investment Conference WARRENVILLE, Ill., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced that President & CEO Vincent J. Arnone is scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City. Presentation Date & Time: September 9, 2025 at 1:00 pm Eastern ...
Cidara Therapeutics to Participate in September Investor Conferences
Cidara Therapeutics to Participate in September Investor Conferences SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences. Details are as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 4:00 PM ETFormat: Corporate Presentation Event: Morgan Stanley 23rd Annual Global Healthcare Conferen...
Medpace Holdings Inc: 1 director
A director at Medpace Holdings Inc sold 37,393 shares at 475.875USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical ...
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conferenc...
Moody's Ratings places Keurig Dr Pepper's ratings under review for dow...
Moody's Ratings (Moody's) today placed Keurig Dr Pepper Inc.'s ("KDP") ratings under review for downgrade, including its Baa1 senior unsecured ratings, and Prime-2 commercial paper (CP) rating. The outlook was changed to ratings under review from stable. We placed the ratings of KDP under review f...
Fuel Tech Awarded Air Pollution Control Orders Totaling $3.2 Million
Fuel Tech Awarded Air Pollution Control Orders Totaling $3.2 Million WARRENVILLE, Ill., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced the receipt of air pollution control (APC) orders from new and existing customers in the US, Europe and Southeast Asia. These orders have an aggregate value of approximately $3.2 million. An order was received from a repeat domestic customer to supply a ...
Cidara Therapeutics Provides Corporate Update and Reports Second Quart...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groupsEnd of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA)Closed upsized public offering for gross proceeds of $402.5 million; significantly strengthened balance sheet to conduct planned Phase 3 program for CD388Added to Russell 2000® and Russell 3000® IndexesConference call and webcast today at 5:00 PM Eastern ...
Fuel Tech Reports 2025 Second Quarter Financial Results
Fuel Tech Reports 2025 Second Quarter Financial Results WARRENVILLE, Ill., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today reported financial results for the second quarter ended June 30, 2025. “Our second quarter results, along with ongoing developments across our two business segments and our Dissolved Gas Infusion business, strengthen our confidence in delivering improved overall performance in t...
- Jonathan Moreland
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PRGS PROGRESS SOFTWARE CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CTAS CINTAS CORPORATION
CIVB CIVISTA BANCSHARES
MEDP MEDPACE HOLDINGS INC.
DYN DYNEGY INC.
PETS PETMED EXPRESS INC.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
PGC BRIDGEWATER BANCSHARES
LOOP PEAPACK-GLADSTONE FINANCIAL CORP.
CHMG LOOP INDUSTRIES
A2JHXF CHEMUNG FINANCIAL CORP.
FVCB CEVA LOGISTICS AG
FGBI FVCBANKCORP
REZI FIRST GUARANTY BANCSHARES
GRX RESIDEO TECHNOLOGIES
PCB INC.
FRHC THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV PACIFIC CITY FINANCIAL CORP
KYMR FREEDOM HOLDING CORP
DMAC COMMUNITY BANCORP INC. VT
NSPR KYMERA THERAPEUTICS
BRCC DIAMEDICA THERAPEUTICS INC.
BPRN INSPIREMD INC
STRW BRC INC
PMNT BANK OF PRINCETON
NYC STRAWBERRY FIELDS REIT INC.
GF PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
FGEN INC.
BMNR THE NEW GERMANY FUND
NEGG INC.
LIONSGATE STUDIOS CORP
FIBROGEN INC.
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ALLE ALLEGION PLC
TMUS T-MOBILE US INC.
TRU TRANSUNION
ROL ROLLINS INC.
MXL MAXLINEAR INC
LVS LAS VEGAS SANDS CORP.
ICLR ICON PLC
FCN FTI CONSULTING INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
CHDN CHURCHILL DOWNS INCORPORATED
MEDP MEDPACE HOLDINGS INC.
KFRC KFORCE INC.
RELL RICHARDSON ELECTRONICS LTD.
ADT ADT INC
KOD KODIAK SCIENCES
FTREV FORTREA HOLDINGS INC.
OUST OUSTER INC
CTNM CONTINEUM THERAPEUTICS INC
UPB UPSTREAM BIO INC
UMAC UNUSUAL MACHS INC NEV
MIMI MINT INCORPORATION LTD
ALMU AELUMA INC
- Jonathan Moreland
Fuel Tech Schedules 2025 Second Quarter Financial Results and Conferen...
Fuel Tech Schedules 2025 Second Quarter Financial Results and Conference Call WARRENVILLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today announced that it will issue its financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after the close of the stock market. Management will host a conference call on Wednesday, August 6, 2025 at 10:00 am ET / 9:00 am CT to ...
Cidara Therapeutics to Report Second Quarter 2025 Financial Results an...
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss t...
- Jonathan Moreland
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
CIVB CIVISTA BANCSHARES
NXRT NEXPOINT RESIDENTIAL TRUST INC.
DYN DYNEGY INC.
GIII G-III APPAREL GROUP LTD.
PETS PETMED EXPRESS INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
DOMO BRIDGEWATER BANCSHARES
FGBI DOMO INCORPORATED
PVH FIRST GUARANTY BANCSHARES
GRX PHILLIPS-VAN HEUSEN CORPORATION
INLX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
FRHC INTELLINETICS
CMTV INC.
RZLT FREEDOM HOLDING CORP
KYMR COMMUNITY BANCORP INC. VT
BTBT REZOLUTE
TERN INC.
CTO KYMERA THERAPEUTICS
VERA BIT DIGITAL (N SHARES)
IMRX TERNS PHARMACEUTICALS
BRCC CONSOLIDATED-TOMOKA LAND CO
BPRN VERA THERAPEUTICS INC
PMNT IMMUNEERING CORP
NYC BRC INC
ACTU BANK OF PRINCETON
MBRX PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
THAR INC.
FGEN ACTUATE THERAPEUTICS INC.
CCIF MOLECULIN BIOTECH INC.
BMNR LIONSGATE STUDIOS CORP
NEGG THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRVL CORVEL CORP.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
RSSS RESEARCH SOLUTIONS
BWB BRIDGEWATER BANCSHARES
DOMO DOMO INCORPORATED
FGBI FIRST GUARANTY BANCSHARES
PVH PHILLIPS-VAN HEUSEN CORPORATION
AMPY AMPLIFY ENERGY
INLX INTELLINETICS
FRHC INC.
CMTV FREEDOM HOLDING CORP
RZLT COMMUNITY BANCORP INC. VT
KYMR REZOLUTE
WSC INC.
BTBT KYMERA THERAPEUTICS
TERN WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB BIT DIGITAL (N SHARES)
CTO TERNS PHARMACEUTICALS
VERA NUVATION BIO INC (A)
IMRX CONSOLIDATED-TOMOKA LAND CO
XLO VERA THERAPEUTICS INC
SSBK IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU PERFECT MOMENT LTD.
SUNS NEW YORK CITY REIT
MBRX INC.
LION ACTUATE THERAPEUTICS INC.
HYMC SUNRISE REALTY TRUST
THAR MOLECULIN BIOTECH INC.
FGEN LIONSGATE STUDIOS CORP
CCIF HYCROFT MINING HOLDING CORPORATION
BTCS THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
TOUCHIT TECHNOLOGIES
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.